Therapy: SGLT inhibition in T1DM - definite benefit with manageable risk

Nat Rev Endocrinol. 2017 Dec;13(12):698-699. doi: 10.1038/nrendo.2017.139. Epub 2017 Oct 27.

Authors

Ele Ferrannini¹, Anna Solini²

Affiliations

¹ CNR Institute of Clinical Physiology, Via Roma 67, Pisa, PI 56100, Italy.
² University of Pisa, Department of Clinical and Experimental Medicine, Via Roma 67, Pisa, I-56126, Italy.

PMID: 29076505
DOI: 10.1038/nrendo.2017.139

No abstract available

Publication types

Comment

MeSH terms

Diabetes Mellitus, Type 1*
Glycosides
Humans
Insulin
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Glycosides
Insulin
Sodium-Glucose Transporter 2 Inhibitors
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol